Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.

Bone marrow transplantation - 1 Feb 2025

Christopher Mary R, Nawas Mariam T, Reagan John L

Abstract excerpt

NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and is mainly classified as favorable or intermediate-risk according to the European Leukemia Net stratification. Some patients, however, either have a poor response to initial intensive chemotherapy or ultimately relapse. NPM1 mutations are common, generally stable at early relapse and AML specific, features which make them ideal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to NPM1 gene
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplasm, Residual

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Prognosis

Source

Identifiers

PMID: 39537780
DOI: 10.1038/s41409-024-02465-2

Genes

NPM1
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.PMID 39537780Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemiaSemantic proximity Read ↗

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.Semantic proximity Read ↗

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.Semantic proximity Read ↗

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Semantic proximity Read ↗

MRD evaluation of AML in clinical practice: are we there yet?Semantic proximity Read ↗

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.Semantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.